In:
The Journal of Immunology, The American Association of Immunologists, Vol. 192, No. 1_Supplement ( 2014-05-01), p. 197.11-197.11
Abstract:
Mesenchymal stem/stromal cells (MSCs) have the remarkable ability to protect tissues by modulating immune responses in various autoimmune diseases. We here investigated that systemic administration of MSCs might prevent development of experimental autoimmune uveitis (EAU) in mice. The study was conducted in conformance with the FASEB Statement of Principles for the use of animals in research and education. Analysis of the retina during the efferent phase revealed that a single intraperitoneal injection of human bone marrow-derived MSCs (hMSCs) at the time of immunization markedly protected the retina from inflammation-mediated damage and suppressed levels of innate and adaptive pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, IFN-γ, IL-17A, and IL-2 in the eye. Analysis of draining lymph nodes (DLNs) during the afferent phase showed that hMSCs significantly decreased the proportions of IL-17- or IFN-γ-expressing CD4+ T cells as well as levels of their cytokines, IL-17A and IFN-γ. The levels of IL-1β, IL-6, IL-12, and IL-23 were not decreased by hMSCs. However, hMSCs significantly increased the level of immunoregulatory cytokine IL-10 and markedly induced the population of IL-10+B220+CD19+ cells in DLNs. Together, data demonstrate that systemic administration of hMSCs attenuates EAU by inducing IL-10-secreting B220+CD19+ cells and by suppressing the Th1/Th17 immune responses.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.192.Supp.197.11
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2014
detail.hit.zdb_id:
1475085-5
Permalink